Data Definitions for the National Minimum Core Data Set to support the introduction of Sarcoma Quality Performance Indicators

Transcription

1 Sarcoma Data Definitions for the National Minimum Core Data Set to support the introduction of Sarcoma Quality Performance Indicators Definitions developed by ISD Scotland in Collaboration with the Sarcoma Quality Performance Indicator Development Group Version 3.0: July 2018 To be used in conjunction with: 1. Sarcoma Clinical Quality Performance Indicators (Latest Published Version). 2. Sarcoma QPI Dataset Validations (Latest Published Version). 3. Sarcoma Measurability of Quality Performance Indicators (Latest Published Version).

2 DOCUMENT CONTROL SHEET Key Information Title Date Published/Issued July 2018 Date Effective From Version/Issue Number V3.0 Document Type Document Status Standard Audience Cross References Author Sarcoma Data Definitions for Minimum Core Dataset for Quality Performance Indicators (QPIs) 1 st April 2018 (TNM 8 changes effective from 1 st April 2018) Guidance Final NHS staff involved in implementing and recording Sarcoma Quality Performance Indicators. Sarcoma Quality Performance Indicators Sarcoma Measurability of Quality Performance Indicators Information Services Division of NHS National Services Scotland Revision History Version Date Summary of Changes V2.0 March 2015 Changes agreed after QA of validation documents and Changes agreed at 9mth Review. V2.1 July 2015 Changes agreed out with review to support data collection. V2.2 Nov 2015 Changes agreed out with review to support data collection. V2.3 Aug 2016 Changes agreed at Baseline Review V2.4 Jul 2017 Changes agreed out with review to support data collection. V2.5 September Changes agreed out 2017 with review to support data collection. V2.6 April 2018 Changes agreed out with review to support data collection V3.0 July 2018 Changes agreed at Formal Review Name Jane Garrett Jane Garrett Jane Garrett Charlotte Anthony Jane Garrett Hannah Ebbins Jane Garrett Jane Garrett Changes Marked See page iii See page iii See page iii See page iii See page iii See page iii See page iii See page iii

3 CONTENTS PREFACE... i NOTES FOR IMPLEMENTATION OF CHANGES... ii CONVENTIONS... ii REVISIONS TO DATASET:... iii CRITERIA FOR INCLUSION OF PATIENTS IN AUDIT... xiii DOWNLOAD FORMAT... xiv Section 1: Demographic Items... 1 Person Family Name (at Diagnosis)... 2 Person Given Name... 3 Patient Postcode at Diagnosis... 4 Date of Birth... 5 Person Sex at Birth... 6 CHI Number... 7 Section 2: Pre-treatment Imaging & Staging Investigations... 8 Location of Diagnosis {Cancer}... 9 Site of Origin of Primary Tumour {Cancer} Location of Sarcoma Date of Histological Diagnosis {Sarcoma} TNM Tumour Classification (Clinical) {Sarcoma} TNM Nodal Classification (Clinical) {Sarcoma} TNM Metastases Classification (Clinical) {Sarcoma} Date Staging CT Scan Complete Date Staging CT Scan Report WHO/ ECOG Performance Status Date Discussed by Care Team (MDT) Type of First Cancer Treatment Date of First Cancer Treatment Date of Definitive Treatment {Sarcoma} Section 3: Surgery Location Code {Cancer Surgery} Consultant in Charge of Surgery Date of Surgery Presentation Type (Surgical) Intent of Surgery Final Definitive (or Only) Surgery Performed (Surgery) {Sarcoma} Primary Flap Reconstruction Section 4: Pathological Details Morphology of Tumour Surgical Margins TNM Tumour Classification (Pathological) {Sarcoma} TNM Nodal Classification (Pathological) {Sarcoma} TNM Metastases Classification (Pathological) {Sarcoma} TNM Histopathological Tumour Grade {Soft Tissue Sarcoma} Gastrointestinal Stromal Tumour (GIST) Risk Score Mutational Analysis (GIST) Date of Mutational Analysis (GIST) Section 5: Oncology Radiotherapy Course Type {Sarcoma} Date Treatment Started (Radiotherapy) {Sarcoma} Date Treatment Completed (Radiotherapy) {Sarcoma} Type of Systemic Anti-Cancer Therapy (SACT) {Sarcoma} Multi-agent Chemotherapy {Sarcoma} Biological Therapy Agent {Sarcoma} Date Treatment Started Systemic Anti-Cancer Therapy (SACT) {Sarcoma} Date Treatment Completed Systemic Anti-Cancer Therapy (SACT) {Sarcoma} Section 6: Clinical Trials Patient Entered into Clinical Trial Section 7: Death Details Date of Death... 72

4 PREFACE Following the publication of Better Cancer Care: An Action Plan in October 2008, the Scottish Government established the Scottish Cancer Taskforce to oversee its implementation. The NHS Scotland Healthcare Quality Strategy in 2010 expands on this by articulating quality ambitions. A quality measurement framework has been developed setting out measures and targets which will be used to monitor, challenge, manage and report progress. Part of this strategy is the development of quality performance indicators (QPIs) to drive quality improvement in cancer care throughout NHS Scotland. As high quality data are required to enable comparisons over time and between regions, it is important that national data definitions are used to facilitate consistent data collection. National data definitions already in use have been used as much as possible to allow electronic data capture, thereby minimising duplication of data collection. Where national data definitions do not already exist, definitions used in other systems have been incorporated. To ensure that findings are comparable across Scotland, the national dataset and data definitions in conjunction with the final quality performance indicators were agreed through public engagement and are now ready for implementation for patients diagnosed from 1 st April i

5 NOTES FOR IMPLEMENTATION OF CHANGES The following changes should be implemented for all patients who are diagnosed with Sarcoma on or after 1 st April 2018, who are eligible for inclusion in the Sarcoma cancer audit. NB: Dataset applies for data reported within the reporting cohort with the exception of the following data item which should be applied for patients diagnosed from 1 st April 2017: Gastrointestinal Stromal Tumour (GIST) Risk Score Changes to definitions fall into the following categories: to address problems with ongoing audit and standardise data definitions, where feasible, between different cancer sites to address problems with existing definitions to allow Quality Performance Indicators to be measured and reported against If you have difficulties in using individual definitions within this document please contact General Enquiries on the Collection of the Minimum Core Data Set If you have any comments on the attached data definitions ISD would welcome your feedback. Please contact: NSS.ISDCANCERAUDIT@NHS.NET CONVENTIONS The layout for each item is standard as shown below where it is applicable: Common Name(s): Main Source of Data Item Standard: Definition: Field Name: Field Type: Field Length: Notes for Users: Codes and Values: Related Data Item(s): In addition the following two conventions have been used in the document: {curly brackets} - definition relates to one specific named data set 'described elsewhere' - indicates there is a definition for the named item within this document ii

6 REVISIONS TO DATASET: Revisions (07/2018 Changes agreed at Formal Review) Database Specification: Delete Measurement of Macroscopic Residual Disease Delete Systemic Therapy Agent {Sarcoma} Add new data item Date Staging CT Scan Report Field Name: CTREPORTDATE, Field Type: Date (DD/MM/CCyy), Field Length: 10 Add new data item Multi-agent Chemotherapy {Sarcoma} Field Name: MULTAGENT, Field Type: Integer, Field Length: 2 Dataset Site of Origin of Primary Tumour {Cancer} - Required for QPI(s): delete 5, 11 Location of Sarcoma - Required for QPI(s): Delete 8, add 5 Date of histological Diagnosis {Sarcoma} - Required for QPI(s) change 1 to 1-11 ; Notes for Users add Required for national survival analysis and national comparative analysis. TNM Tumour Classification (Clinical) {Sarcoma} Notes for Users delete This may be at any MDT meeting up until first treatment however, add Within the table below the following sites are classified as bone sarcomas: Appendicular skeleton, trunk, skull and facial bones; Spine and Pelvis, The following sites are classified as soft tissue sarcomas: Extremity and superficial trunk; Retroperitoneum; Head & Neck; Thoracic and Abdominal viscera; Codes and Values table reformatted. TNM Nodal Classification (Clinical) {Sarcoma} - Notes for Users delete This may be at any MDT meeting up until first treatment however. TNM Metastases Classification (Clinical) {Sarcoma} - Notes for Users delete This may be at any MDT meeting up until first treatment however ; add Where the presence of distant metastases has been documented this should be recorded as M1. Where the absence of metastases has been documented this should be recorded as M0. Date Staging CT Scan Complete Delete Required for QPI(s): 3 Date Staging CT Scan Report Add new data item, see entry for full detail Type of First Cancer Treatment - Required for QPI(s) add 6, 9 ; Codes and Values add code 16 Hormone therapy Date of First Cancer Treatment - Required for QPI(s) delete 2, 10 ; Notes for users add If hormone therapy is the first treatment, it is not always clearly documented when hormone therapy starts. In the patient discharge or clinic letter the clinician may ask the GP to prescribe hormone therapy, in this case, record the date as two days from the day the discharge letter or clinic letter was typed iii

7 Date of Definitive Treatment Notes for Users add Where this has subsequently been confirmed at MDT, the date of MDT should be recorded Date of Surgery - Required for QPI(s): delete 3, 9 add 11 Intent of Surgery - Required for QPI(s): delete 4 Final Definitive (or Only) surgery Performed (Surgery) {Sarcoma} - Required for QPI(s): delete 8, 10 Add code V14.4 excision of lesion of mandible Measurement of Macroscopic Residual Disease Remove data item Surgical Margins - Required for QPI(s): delete 8 TNM Tumour Classification (Pathological) {Sarcoma} Notes for Users add Within the table below the following sites are classified as bone sarcomas: Appendicular skeleton, trunk, skull and facial bones; Spine and Pelvis, The following sites are classified as soft tissue sarcomas: Extremity and superficial trunk; Retroperitoneum; Head & Neck; Thoracic and Abdominal viscera; Codes and Values table reformatted. TNM Histopathological Tumour Grade {Soft Tissue Sarcoma} - Required for QPI(s): delete 8 Gastrointestinal Stromal Tumour (GIST) Risk Codes and Values table updated Type of Systemic Anti-Cancer Therapy (SACT) {Sarcoma} - Required for QPI(s): delete 9 Systemic Therapy Agent {Sarcoma} Remove data item Multi-agent Chemotherapy {Sarcoma} - Add new data item, see entry for full detail Revisions to Dataset outwith review (April 2018) Final Definitive (or Only) Surgery Performed (Surgery) {Sarcoma} the following codes have been inserted S08.1 Curettage and cauterisation of lesion of skin of head or neck P05.4 Excision of lesion of vulva NEC G50.1 Excision of lesion of duodenum G59.1 Excision of lesion of jejunum L79.8 Other specified other operations on vena cava M41.1 Open extirpation of lesion of bladder S17.9 Unspecified distant flap of skin and muscle S27.9 Unspecified other local flap of skin T33.1 Open excision of lesion of peritoneum T37.1 Excision of lesion of mesentery of small intestine T37.8 Other specified operations on mesentery of small intestine T37.9 Unspecified operations on mesentery of small intestine V14.1 Hemimandibulectomy V24.8 Other specified decompression operations on thoracic spine V25.4 Primary posterior laminectomy decompression of lumbar spine iv

8 Y75.1 Laparoscopically assisted approach to abdominal cavity Site of Origin of Primary Tumour {Cancer} the following codes have been inserted C44.4 Skin of scalp and neck C44.5 Skin of trunk C17.1 Jejunum C17.2 Ileum C54.1 Endometrium TNM Histopathological Tumour Grade {Soft Tissue Sarcoma} G2 Low grade should be changed to G2 intermediate grade. Morphology of Tumour - add 8930/3 Endometrial stromal sarcoma TNM Tumour Classification (Clinical) {Sarcoma} - Standard and Definition changed from Seventh Edition, 2009 to Eighth Edition 2017; Remove codes and values table and insert new codes and values tables; Remove 8 from Required from QPIs TNM Nodal Classification (Clinical) {Sarcoma} - Standard and Definition changed from Seventh Edition, 2009 to Eighth Edition 2017, Add * to Regional lymph nodes cannot be assessed and add *NX: Regional lymph node involvement is rare for GISTs, so that cases in which the nodal status is not assessed clinically or pathologically could be considered N0 instead of NX. ; Remove 8 from Required from QPIs TNM Metastases Classification (Clinical) {Sarcoma} - Standard and Definition changed from Seventh Edition, 2009 to Eighth Edition 2017; Remove 8 from Required from QPIs TNM Tumour Classification (Pathological) {Sarcoma} - Standard changed from Seventh Edition, 2009 to Eighth Edition 2017; Remove codes and values table and insert new codes and values tables TNM Nodal Classification (Pathological) {Sarcoma} - Standard changed from Seventh Edition, 2009 to Eighth Edition 2017; Add * to Regional lymph nodes cannot be assessed and add *pnx: Regional lymph node involvement is rare for GISTs, so that cases in which the nodal status is not assessed clinically or pathologically could be considered pn0 instead of pnx. TNM Metastases Classification (Pathological) - Standard changed from Seventh Edition, 2009 to Eighth Edition 2017; delete pm0 - No distant metastasis; add microscopically confirmed to pm1 ; Add Note pm0 and pmx are not valid categories Dataset: (September 2017) Final Definitive (or Only) Surgery Performed (Surgery) {Sarcoma} the following codes have been inserted (Query 1510 & 1519): A38.1 Extirpation of lesion of meninges of cortex of brain Q09.2 Open myomectomy v

9 C01.1 Exenteration of orbit S35.3 Split autograft of skin to head or neck NEC G69.3 Ileectomy and anastomosis of ileum to ileum Y50.2 Laparotomy approach NEC Y75.2 Laparoscopic approach to abdominal cavity NEC T36.1 Omentectomy S Local myocutaneous subcutaneous pedicle flap NEC S36.2 Full thickness autograft of skin NEC Person Family Name (at Diagnosis)(PATSNAME) link updated (Query 1506) Person Given Name (PATFNAME) link updated (Query 1506) Patient Postcode at Diagnosis {Cancer} (PATPCODE) link updated (Query 1506) Date of Birth (DOB) link updated (Query 1506) Site of Origin of Primary Tumour {Cancer} the following code has been inserted (Query 1520): C44.3 Skin of other and unspecified parts of face Dataset: (July 2017) Site of Origin of Primary Tumour {Cancer} the following codes have been inserted C Malignant neoplasm, lip, unspecified C01.X - Malignant neoplasm of base of tongue C Malignant neoplasm, tongue, unspecified C Malignant neoplasm, floor of mouth, unspecified C Malignant neoplasm, palate, unspecified C Malignant neoplasm, mouth, unspecified C07.X - Malignant neoplasm of parotid gland C Malignant neoplasm, major salivary gland, unspecified C Malignant neoplasm, tonsil, unspecified C Malignant neoplasm, oropharynx, unspecified C Malignant neoplasm, nasopharynx, unspecified C12.X - Malignant neoplasm of pyriform sinus C Malignant neoplasm, hypopharynx, unspecified C19.X - Malignant neoplasm of rectosigmoid junction C20.X - Malignant neoplasm of rectum C Malignant neoplasm, liver, unspecified C23.X - Malignant neoplasm of gall bladder C Malignant neoplasm, biliary tract, unspecified C Malignant neoplasm, pancreas, unspecified C Malignant neoplasm, ill-defined sites within the digestive system C Malignant neoplasm, accessory sinus, unspecified C33.X - Malignant neoplasm of trachea C37.X - Malignant neoplasm of thymus C Malignant neoplasm, ill-defined sites within the respiratory system C Malignant neoplasm, bone and articular cartilage of limb, unspecified C Malignant neoplasm, bone and articular cartilage, unspecified C Malignant neoplasm, of skin, unspecified C Malignant neoplasm, peripheral nerves and autonomic nervous system, unspecified vi

10 C Malignant neoplasm, breast, unspecified C Malignant neoplasm, vulva, unspecified C52.X - Malignant neoplasm of vagina C Malignant neoplasm, corpus uteri, unspecified C55.X - Malignant neoplasm of uterus, part unspecified C56.X - Malignant neoplasm of ovary C Malignant neoplasm, female genital organ, unspecified C58.X - Malignant neoplasm of placenta C Malignant neoplasm, penis, unspecified C Malignant neoplasm, testis, unspecified C Malignant neoplasm, male genital organ, unspecified C64.X - Malignant neoplasm of kidney, except renal pelvis C65.X - Malignant neoplasm of renal pelvis C66.X - Malignant neoplasm of ureter C Malignant neoplasm, bladder, unspecified C Malignant neoplasm, urinary organ, unspecified C Malignant neoplasm, eye, unspecified C Malignant neoplasm, meninges, unspecified C Malignant neoplasm, brain, unspecified C Malignant neoplasm, central nervous system, unspecified C73.X - Malignant neoplasm of thyroid gland C Malignant neoplasm, adrenal gland, unspecified C Malignant neoplasm, endocrine gland, unspecified C Malignant neoplasm, lymph node, unspecified C80.X - Malignant neoplasm of unspecified site C Malignant neoplasm of lymphoid, haematopoietic/related tissue, unspecified Morphology of Tumour the following code has been inserted; 8811/1 Cellular Fibroma Dataset (Baseline Review Aug 2016) Location of Diagnosis inserted the following text within notes for users GP surgery codes can be recorded in this field if this is the location the diagnosis was first made. Site of Origin of Primary Tumour {Cancer} the following codes have been inserted C17.0 Duodenum C32.9 Larynx unspecified C Solitary malignant fibrous tumour of the lung C Dermatofibrosarcoma C44.6 Skin of Upper limb, including shoulder C44.7 Skin of lower limb, including hip C47.1 Peripheral Nerves of Upper limb, including shoulder C47.2 Peripheral Nerves of Lower limb including hip C47.5 Peripheral Nerves of pelvis C50.0 Phylloides tumour C53.9 Leiomyosarcoma of the cervix C63.1 Liposarcoma of the Spermatic cord TNM Tumour Classification (Clinical) {Sarcoma} and TNM Tumour Classification (Pathological) {Sarcoma} the following text has been inserted within notes for users vii

11 Sarcoma that are diagnosed at surgery with no pre-treatment investigations should be recorded as not applicable (96). For gynaecological sarcomas, no TNM is required and should be recorded as not applicable (96). TNM Nodal Classification (Clinical) {Sarcoma} and TNM Nodal Classification (Pathological) {Sarcoma} the following text has been inserted within notes for users Sarcoma that are diagnosed at surgery with no pre-treatment investigations should be recorded as not applicable (96). For gynaecological sarcomas, no TNM is required and should be recorded as not applicable (96). TNM Metastases Classification (Clinical) {Sarcoma} and TNM Metastases Classification (Pathological) {Sarcoma}- the following text has been inserted within notes for users Sarcoma that are diagnosed at surgery with no pre-treatment investigations should be recorded as not applicable (96). For gynaecological sarcomas, no TNM is required and should be recorded as not applicable (96). Date Staging CT Scan Complete the following text has been inserted within notes for users The CT carried out closest to the date of diagnosis should be used. If this is not clear or if Date... Date of First Cancer Treatment the following text first date the decision was taken not to give the patient treatment as part of their primary therapy has been removed and replaced with the date the MDT recommend supportive care as the treatment option. Presentation Type (Surgical) the following text has been removed from the explanatory notes for code 02 Emergency If presentation is classed as urgent, code as emergency only if surgery is performed within 72 hours of admission Final Definitive (or Only) Surgery Performed (Surgery) {Sarcoma} - the following codes have been inserted A44.4 Excision of extradural lesion B25.1 Excision of lesion of adrenal gland E03.2 Excision of lesion of septum of nose E Total Laryngectomy G Excision of duodenum Excludes: Pancreaticoduodenectomy (J56) G Gastroduodenectomy G Total excision of duodenum G49.3 Partial excision of duodenum G Excision of duodenum Other specified G Excision of duodenum Unspecified G51.0- Bypass of duodenum Excludes: Bypass of duodenum by anastomosis of duodenum to colon (G51.4) G Bypass of duodenum by anastomosis of stomach to jejunum G Bypass of duodenum by anastomosis of duodenum to duodenum G Bypass of duodenum by anastomosis of duodenum to jejunum G Bypass of duodenum Other specified G Bypass of duodenum Unspecified G69.9 Excision of ileum unspecified J56.2 Pancreaticoduodenectomy and resection of antrum of stomach (Whipple s resection) L79.7 Excision of lesion of vena cava viii

12 M02.5 Nephrectomy NEC S06.5 Excision of lesion of skin of head or neck NEC S06.7 Re-excision of skin margins NEC S06.9 Other excision of lesion of skin unspecified T39.1 Excision of lesion of posterior peritoneum V25.1 Primary extended decompression of lumbar spine and intertransverse fusion of joint of lumbar spine V25.7 Primary anterior corpectomy of lumbar spine and reconstruction HFQ V67.2 L2 Hemilaminectomy Includes: Duodenectomy not elsewhere classified Morphology of Tumour the following code has been inserted 8936/1 - Gastrointestinal stromal tumour, NOS Gastrointestinal Stromal Tumour (GIST) Risk Score the following text Risk of Aggressive Behaviour in GISTs (from Fletcher et al 2002, Human Pathology 33(5): It is frequently referred to either as the NIH risk table or as the Fletcher risk table. Replaced with Risk of Progressive Disease (Gastric) (from Miettinen M, Lasota J. Semin Diagn Pathol 2006:23: This is included in the Royal College of Pathologists Dataset for Gastrointestinal Stromal Tumours (GISTs). If the risk score is not documented, or there are any inconsistencies the score should not be calculated and the relevant pathologist should be contacted for clarification. Codes and Values (Fletcher table replaced with Miettinen (below)) Code Value Size Mitotic Index Explanatory Note None 2 cm 5 (in 5mm 2 ) Very low (1.9%) >2-5 cm 5 (in 5mm 2 ) Low (3.6%) >5-10cm 5 (in 5mm 2 ) Moderate (10%) >10 cm 5 (in 5mm 2 ) Insufficient data 2 cm >5 (in 5mm 2 ) Moderate (16%) >2-5 cm >5 (in 5mm 2 ) High (55%) >5-10cm >5 (in 5mm 2 ) High (86%) >10 cm >5 (in 5mm 2 ) 96 Not applicable Not gastrointestinal stromal tumour 99 Not known Includes not recorded Radiotherapy Course Type {Sarcoma} 1-3 the following text inserted in notes for users For patients undergoing chemoradiotherapy the radiotherapy element should be recorded as code 06. The Chemotherapy element of this combined treatment should be recorded separately in fields CHEMTYPE1, CHEMTYPE2 or CHEMTYPE3. The following codes and values added; 05 Radical It is primary treatment and is given with curative intent. 06 Chemoradiotherapy Radical radiotherapy given in combination with chemotherapy, either concurrently or sequentially. ix

13 Type of Systemic Anti-Cancer Therapy (SACT) {Sarcoma} 1-3 the following text inserted in notes for users For patients undergoing chemoradiotherapy the radiotherapy element should be recorded as code 08 and recorded in Radiotherapy Course Type [RCOURSETYPE1, RCOURSETYPE2 and RCOURSETYPE3]. The following code and value added; 08 Chemoradiotherapy Chemotherapy given in combination with radical radiotherapy either concurrently or sequentially. Systemic Therapy Agent {Sarcoma} 1-3 or biological therapy removed from the definition. Dataset (November 2015): (Query 1014/ 1044) Morphology of Tumour - ICD10 code C61._ added to the morphology list alongside morphology code 8980/3 Carcinosarcoma NOS; add morphology code 9020/3 Phyllodes tumour, malignant (C50._) (Query 1030) TNM Tumour Classification (Clinical) {Sarcoma} - add code 96 Not applicable TNM Nodal Classification (Clinical) {Sarcoma} add code 96 Not applicable TNM Metastases Classification (Clinical) {Sarcoma} add code 96 Not applicable (Query 1033) Radiotherapy Course Type {Sarcoma}1-3 Delete from notes for users For patients undergoing chemoradiotherapy the radiotherapy element should be recorded as code 06 and recorded also in SACT under code 05 Type of Systemic Anti-Cancer Therapy (SACT) {Sarcoma} 1-3 (CHEMTYPE1) Delete from notes for users For patients undergoing chemoradiotherapy the chemotherapy element should be recorded as code 05 and recorded also in Radiotherapy Course Type) under code 06. (Query 1072) Final Definitive (or Only) Surgery Performed (Surgery) {Sarcoma} (OPCODE1) add V05.1 Extirpation of lesion of cranium Dataset (July 2015): Location of Diagnosis {Cancer} remove X1010=Not applicablesite of Origin of Primary Tumour {Cancer} (SITE) add site code C61 prostate Morphology of tumour - morphology code 8980/3 Carcinosarcoma NOS Database Specification(April 2015): TNM Metastases Classification (Clinical) {Sarcoma} field length 3 Date Staging CT Scan Complete (Pre-treatment) remove word Pre-treatment Date of First Cancer Treatment format (DD/MM/CCYY) Date of Definitive Treatment - format (DD/MM/CCYY)Date of Surgery - format (DD/MM/CCYY) Surgical Margins field type Characters Dataset: Location of Diagnosis Delete Error! Reference source not found Site of Origin of Primary Tumour {Cancer} amend Field Type: Characters, Remove Liver Cell Carcinoma, Update list x

14 Location of sarcoma add Code 96 Not applicable Primary location not known, add Code 03 - GIST TNM Tumour Classification (Clinical) {Sarcoma} change field name ctsarc, add Bone and GIST TNM TNM Nodal Classification (Clinical) {Sarcoma} - change field name cnsarc TNM Metastases Classification (Clinical) {Sarcoma} - change field name cmsarc,and field length 3 add Bone and GIST TNM Date Staging CT Scan Complete (Pre-treatment) remove word Pre-treatment Date Discussed by Care Team (MDT) add Notes to Users This won t necessarily be a Sarcoma MDT Final Definitive (or Only) Surgery Performed (Surgery) {Sarcoma} update list of codes Morphology of tumour add If unsure check with Pathologist, add an explanatory note to code 8851/3 to say Atypical Lipomatous tumour TNM Tumour Classification (Pathological) {Sarcoma} - change field name ptsarc, add Not applicable and Bone and GIST TNM TNM Nodal Classification (Pathological) {Sarcoma} - change field name pnsarc, add Not applicable TNM Metastases Classification (Pathological) {Sarcoma} - change field name pmsarc, Not applicable TNM Histopathological Tumour Grade {Soft Tissue Sarcoma} add to Notes for Users Should be documented and if not check with pathologist, add not assessable code 93.Mutational Analysis (GIST) add 'mutational analysis is not routinely performed for low risk GIST, however if performed this should be recorded' Dataset: (July 2014) Page 10: Date of Diagnosis {Cancer} data item deleted Page 12: Location of Sarcoma addition to Notes for Users Page 13: Date of Histological Diagnosis {Sarcoma} field name amended Page 17: Date Staging CT Scan Complete (Pre-treatment) Note for Users amended Page 19: Date Discussed by Care Team Notes for Users amended Page 22: Date of Definitive Treatment {Sarcoma} data item added Page 29: Final Definitive (or Only) Surgery Performed (Surgery) {Sarcoma} amendment to Codes and Values Page 38: Primary Flap Reconstruction definition amended and amendments made to Notes for users Page 39: Measurement of Macroscopic residual Disease amendment to Notes for Users Page 45: Surgical Margins addition to Notes for Users Page 49: TNM Histopathological Tumour grade {Soft Tissue Sarcoma} Code 04 (High Grade) removed from Codes and Values Page 51: Mutational Analysis (GIST) Code 04 (insufficient sample) added to codes and values Page 52: Date of Mutational Analysis (GIST) addition to Notes for Users Page 54: Radiotherapy Course Type {Sarcoma} code 02 (Radical) and code 06 (Chemoradiotherapy) removed Page 57: Type of Systemic Anti-Cancer Therapy (SACT) {Sarcoma} 1-3 code 05 (Chemoradiotherapy) removed Page 58: Systemic Therapy Agent {Sarcoma} 1-3 Amendment to Notes for Users Database Specification: Date of Definitive Treatment {Sarcoma} data item added: Field Name: DEFTREATDATE, Field Type: Date, Field Length: 10. xi

15 Date of Histological Diagnosis {Sarcoma} field name amended from HDIAG to DIAGDATE xii

16 CRITERIA FOR INCLUSION OF PATIENTS IN AUDIT To facilitate national comparisons the same patients must be audited throughout Scotland. The following eligibility criteria have been documented for this purpose. Include: All patients with a confirmed new primary invasive sarcoma or gastrointestinal stromal tumour (GIST). This includes all patients who have had previous primary malignancy of any site or concurrent primary malignancy of another site. Exclude: Patients where the origin of the primary is uncertain Patients with tumour types other than sarcoma Patients with benign tumours or neoplasms of uncertain/borderline behaviour of soft tissue or bone Patients with metastases originating from another primary site Patients with recurrent disease (as opposed to a new primary) Patient where their only record of their cancer is from a death certificate (DCO) Patients with normal residence outwith Scotland Patients whose definitive cancer treatment was privately funded or undertaken outwith NHS Scotland NB: Only treatments as part of the initial treatment plan should be recorded. xiii

17 DOWNLOAD FORMAT To assist with downloading data to ISD for the National Quality Assurance Programme and other agreed activities, all sites should be able export data according to the following specification. DATABASE SPECIFICATION Data Item Field Name Field Type Size Page Section 1: Demographic Items 1 Person Family Name (at Diagnosis) PATSNAME Characters 35 2 Person Given Name PATFNAME Characters 35 3 Patient Postcode at Diagnosis PATPCODE Characters 8 4 Date of Birth DOB Date (DD/MM/CCYY) 10 5 Person Sex at Birth SEX Integer 2 6 CHI Number CHINUM Characters 10 7 Section 2: Pre-treatment Imaging & Staging Investigations 8 Location of Diagnosis {Cancer} HOSP Characters 5 9 Site of Origin of Primary Tumour {Cancer} SITE Characters 5 10 Location of Sarcoma SITELOCATION Characters 3 14 Date of Histological Diagnosis Date DIAGDATE {Sarcoma} (DD/MM/CCYY) TNM Tumour Classification (Clinical) {Sarcoma} ctsarc Characters 3 16 TNM Nodal Classification (Clinical) {Sarcoma} cnsarc Characters 2 18 TNM Metastases Classification (Clinical) {Sarcoma} cmsarc Characters 3 19 Date Staging CT Scan Complete CTDATE Date (DD/MM/CCYY) Date Staging CT Scan Report CTREPORTDATE Date (DD/MM/CCYY) WHO/ ECOG Performance Status PSTATUS Integer 1 22 Date Discussed by Care Team (MDT) MDTDATE Date (DD/MM/CCYY) Type of First Cancer Treatment FIRSTTREATTYPE Integer 2 24 Date of First Cancer Treatment FIRSTTREATDATE Date (DD/MM/CCYY) Date of Definitive Treatment DEFTREATDATE Date (DD/MM/CCYY) Section 3: Surgery 27 Location Code {Cancer Surgery} HOSPSURG Characters 5 28 Consultant in Charge of Surgery SURGCON Characters Date of Surgery DSURG Date (DD/MM/CCYY) Presentation Type (Surgical) SURGPRESENT Integer 2 31 Intent of Surgery OPINTENT Integer 2 32 xiv

18 Final Definitive (or Only) Surgery Performed (Surgery) {Sarcoma} OPCODE1 Characters 5 33 Final Definitive (or Only) Surgery Performed (Surgery) {Sarcoma} OPCODE2 Characters 5 33 Primary Flap Reconstruction PRIMFLAP Integer 2 45 Section 4: Pathological Details 46 Morphology of Tumour MORPHOL Characters 6 47 Surgical Margins SURGMARG Characters 4 51 TNM Tumour Classification (Pathological) {Sarcoma} ptsarc Characters 4 52 TNM Nodal Classification (Pathological) {Sarcoma} pnsarc Characters 3 54 TNM Metastases Classification (Pathological) {Sarcoma} pmsarc Characters 3 55 TNM Histopathological Tumour Grade {Soft Tissue Sarcoma} TUMGRADE Characters 2 56 Gastrointestinal Stromal Tumour (GIST) Risk Score GISTRISK Integer 2 57 Mutational Analysis (GIST) MUTANALYSIS Integer 2 58 Date of Mutational Analysis (GIST) DMUTANALYSIS Date (DD/MM/CCYY) Section 5: Oncology 60 Radiotherapy Course Type {Sarcoma} 1-3 RCOURSETYPE1 Integer 2 61 Radiotherapy Course Type {Sarcoma} 1-3 RCOURSETYPE2 Integer 2 61 Radiotherapy Course Type {Sarcoma} 1-3 RCOURSETYPE3 Integer 2 61 Date Treatment Started (Radiotherapy) Date RSTARTDATE1 {Sarcoma} 1-3 (DD/MM/CCYY) Date Treatment Started (Radiotherapy) Date RSTARTDATE2 {Sarcoma} 1-3 (DD/MM/CCYY) Date Treatment Started (Radiotherapy) Date RSTARTDATE3 {Sarcoma} 1-3 (DD/MM/CCYY) Date Treatment Completed Date RCOMPDATE1 (Radiotherapy) {Sarcoma} 1-3 (DD/MM/CCYY) Date Treatment Completed Date RCOMPDATE2 (Radiotherapy) {Sarcoma} 1-3 (DD/MM/CCYY) Date Treatment Completed Date RCOMPDATE3 (Radiotherapy) {Sarcoma} 1-3 (DD/MM/CCYY) Type of Systemic Anti-Cancer Therapy (SACT) {Sarcoma} 1-3 CHEMTYPE1 Integer 2 64 Type of Systemic Anti-Cancer Therapy (SACT) {Sarcoma} 1-3 CHEMTYPE2 Integer 2 64 Type of Systemic Anti-Cancer Therapy (SACT) {Sarcoma} 1-3 CHEMTYPE3 Integer 2 64 Multi-agent Chemotherapy {Sarcoma} MULTAGENT Integer 2 65 Biological Therapy Agent {Sarcoma} BIOAGENT Integer 2 66 Date Treatment Started Systemic Anti- Cancer Therapy (SACT) {Sarcoma} 1-3 CHEMDATE1 Date (DD/MM/CCYY) xv 10 67

19 Date Treatment Started Systemic Anti- Cancer Therapy (SACT) {Sarcoma} 1-3 Date Treatment Started Systemic Anti- Cancer Therapy (SACT) {Sarcoma} 1-3 Date Treatment Completed Systemic Anti-Cancer Therapy (SACT) {Sarcoma} 1-3 Date Treatment Completed Systemic Anti-Cancer Therapy (SACT) {Sarcoma} 1-3 Date Treatment Completed Systemic Anti-Cancer Therapy (SACT) {Sarcoma} 1-3 CHEMDATE2 CHEMDATE3 CHEMENDATE1 CHEMENDATE2 CHEMENDATE3 Date (DD/MM/CCYY) Date (DD/MM/CCYY) Date (DD/MM/CCYY) Date (DD/MM/CCYY) Date (DD/MM/CCYY) Section 6: Clinical Trials 69 Patient Entered into Clinical Trial TRIAL Integer 2 70 Section 7: Death Details 71 Date of Death DOD Date (DD/MM/CCYY) xvi

20 Section 1: Demographic Items 1

21 Person Family Name (at Diagnosis) Common Name(s): Surname, Family name Main Source of Data Item Standard: Government Data Standards Catalogue Definition: That part of a person's name which is used to describe family, clan, tribal group, or marital association at the time of diagnosis. Field Name: PATSNAME Field Type: Characters Field Length: 35 Notes for Users: Main Source of Standard: Government Data Standards Catalogue The surname of a person represents that part of the name of a person indicating the family group of which the person is part. It should be noted that in Western culture this is normally the latter part of the name of a person. However, this is not necessarily true of all cultures. This will, of course, give rise to some problems in the representation of the name. This is resolved by including the data item Name Element Position in the structured name indicating the order of the name elements. From SMR Definitions and Codes Notes by Users: 2

22 Person Given Name Common Name(s): Forename, Given Name, Personal Name Main Source of Data Item Standard of Standard: Government Data Standards Catalogue Definition: The forename or given name of a person. Field Name: PATFNAME Field Type: Characters Field Length: 35 Notes for Users: Main Source of Standard: Government Data Standards Catalogue The first forename of a person represents that part of the name of a person which after the surname is the principal identifier of a person. Where the person's preferred forename is not the first forename, the related data item 'Preferred Forename' should be used to indicate this. Notes by Users: 3

23 Patient Postcode at Diagnosis Main Source of Data Item Standard: Government Data Standards Catalogue Definition: Postcode of patient's usual place of residence on the date of diagnosis Field Name: PATPCODE Field Type: Characters Field Length: Maximum 8 Notes for Users: Postcode is included in BS7666 Address (GDSC) but there is also a separate Post Code standard which will be populated from BS7666 Address Post Code. This item can be derived from the date of diagnosis and patient address at that time Related Data Item(s): Date of Diagnosis Notes by Users: 4

24 Date of Birth Main source of Data Item Standard: Government Data Standards Catalogue Definition: The date on which a person was born or is officially deemed to have been born, as recorded on the Birth Certificate.. Field Name: DOB Field Type: Date (DD/MM/CCYY) Field Length: 10 Notes for Users: If the patient's date of birth is recorded differently on different occasions, the most frequently used or latest date should be recorded. The patient's full date of birth inclusive of the century should be recorded. The format should be DD/MM/CCYY e.g. 01/02/2011. Related Data Item(s): CHI Number Notes by Users: 5

25 Person Sex at Birth Common Name(s): Sex at Birth Main Source of Data Item Standard of Standard: Derived from the nearest equivalent Government Data Standards Catalogue standard Person Gender at Registration Definition: This is a factual statement, as far as is known, about the phenotypic (biological) sex of the person at birth Field Name: SEX Field Type: Integer Field Length: 2 Notes for Users: A person s sex has clinical implications, both in terms of the individual s health and the health care provided to them. In the majority of cases, the phenotypic (biological) sex and genotypic sex are the same and the phenotypic sex is usually easily determined. In a small number of cases, accurate determination of genotype may be required Codes and Values: Code Value Explanatory Notes 01 Male 02 Female 09 Not specified/indeterminate Where it has not been possible to determine if the person is male or female at birth, e.g. intersex / hermaphrodite. 99 Not recorded Related Data Item(s): CHI Number Notes by Users: 6

26 CHI Number Main Source of Data Item Standard of Standard: Department. Scottish Executive Health Definition: The Community Health Index (CHI) is a population register, which is used in Scotland for health care purposes. The CHI number uniquely identifies a person on the index. Field Name: CHINUM Field Type: Characters Field Length: 10 Notes for Users: The Community Health Index (CHI) is a computer based population index whose main function at present is to support primary care services. CHI contains details of all Scottish residents registered with a General Practitioner and was originally envisaged and implemented as a population-based index to help assess the success of immunisation and screening programmes. It is therefore closely integrated with systems for child health, cervical cytology and breast screening call and recall It is intended that this number, the Scottish equivalent of the new NHS number in England and Wales, should become the Unique Patient Identifier throughout the NHS in Scotland. From Designed to Care - Scottish Office The CHI number is a unique numeric identifier, allocated to each patient on first registration with the system. The CHI number is a 10-character code consisting of the 6-digit date of birth (DDMMYY), two digits, a 9th digit which is always even for females and odd for males and an arithmetical check digit. (ISD, Information Services, NHS National Services Scotland) The CHI number should always be used to identify a patient. However, Health record identifiers, such as hospital numbers in Patient Administration Systems (PAS), may be used locally, in conjunction with the CHI number or in the absence of the CHI number, to track patients and their records. Although there may be no number when a patient presents for treatment, there must be an allocation at some point in the episode of care as CHI is mandatory on all clinical communications. Non-Scottish patients and other temporary residents can have a CHI number allocated if required but it is envisaged that future development may allow the identifying number used in other UK countries to be used in Scotland. Related Data Item(s): Date of Birth, Person Sex at Birth. Notes by Users: 7

27 Section 2: Pre-treatment Imaging & Staging Investigations 8

28 Location of Diagnosis {Cancer} Main Source of Data Item Standard: The National Audit Cancer Datasets developed by the regional Cancer Networks supported by Information Services. Definition: The patient's hospital of investigation in which the diagnosis of cancer was first made. Field Name: HOSP Field Type: Characters Field Length: 5 Notes for Users: Required for analysis purposes and clarifying responsibility for data collection. Details of location codes for hospitals can be found in the "Definitions and Codes for the NHS in Scotland" manual produced by ISD Scotland. Location codes for hospitals are five character codes maintained by ISD Scotland and the General Register Office (Scotland). The first character denotes the health board, the next three are assigned and the fifth denotes the type of location (H=hospital) e.g. A111H=Crosshouse Hospital G107H=Glasgow Royal Infirmary X9999=Not recorded If a patient was provisionally diagnosed at one hospital but transferred to another for confirmation of the diagnosis only e.g. biopsy, then returns to the original hospital, the first hospital should be recorded as the Location of diagnosis. GP surgery codes can be recorded in this field if this is the location the diagnosis was first made. Codes and Values: Related Data Items: 9

29 Site of Origin of Primary Tumour {Cancer} Main Source of Data Item Standard: The World Health Organisation (WHO) and the Cancer Registration New Data definitions for Socrates (August 1999 Version 8.0). Definition: The anatomical site of origin of the primary tumour according to the International Classification of Diseases (ICD-O(3)). Field Name: SITE Field Type: Characters Field length: 5 Notes for Users: Required for QPI(s): 1, 2, 3, 4, 6, 7, 8 For ICD-O(3), tumours should be assigned to the subcategory that includes the point of origin of the tumour. A tumour that overlaps the boundaries of two or more subcategories and whose point of origin cannot be determined should be classified as subcategory C49.8. It should be noted that this subcategory should only be used where it is impossible to identify the specific site of origin of the tumour. Codes and Values: ICD-10 Value Code C00.9 Malignant neoplasm, lip, unspecified C01.X Malignant neoplasm of base of tongue C02.9 Malignant neoplasm, tongue, unspecified C03.9 Gum, unspecified C04.9 Malignant neoplasm, floor of mouth, unspecified C04.9 C05.9 Malignant neoplasm, palate, unspecified C05.9 C06.9 Malignant neoplasm, mouth, unspecified C06.9 C07.X Malignant neoplasm of parotid gland C07.X C08.9 Malignant neoplasm, major salivary gland, unspecified C08.9 C09.9 Malignant neoplasm, tonsil, unspecified C09.9 C10.9 Malignant neoplasm, oropharynx, unspecified C10.9 C11.9 Malignant neoplasm, nasopharynx, unspecified C11.9 C12.X Malignant neoplasm of pyriform sinus C12.X C13.9 Malignant neoplasm, hypopharynx, unspecified C15.0 Cervical oesophagus C15.1 Thoracic oesophagus Notes on Inclusion C13.9 C15.2 Abdominal part of oesophagus C15.3 Upper third of oesophagus Proximal third of oesophagus Up to 20cm from back of teeth C15.4 Middle third of oesophagus 20-30cm from back of teeth C15.5 Lower third of oesophagus Distal third of oesophagus 30-40cm from back of teeth C15.8 Overlapping lesion of oesophagus 10

30 C15.9 Oesophagus, NOS C16.0 Cardia, NOS Gastric cardio Cardio-oesophageal junction Oesophagogastric Junction C16.1 Fundus of stomach Gastric fundus C16.2 Body of stomach Corpus of stomach Gastric corpus C16.3 Gastric antrum Antrum of stomach Pyloric antrum C16.4 Pylorus Prepylorus Pyloric canal C16.5 Lesser curvature of stomach, unspecified Lesser curvature of stomach, not classifiable to C16.0 C16.4 C16.6 Greater curvation of stomach, unspecified Greater curvature of stomach, not classifiable to C16.0 C16.4 C16.8 Overlapping lesion of the stomach Anterior wall of stomach, NOS Not classifiable to C16.0 to C16.4 Posterior wall of stomach, NOS Not classifiable to C16.0 to c16.4 C16.9 Stomach, unspecified Gastric, NOS C17.0 Duodenum C17.1 Jejunum C17.2 Ileum C17.9 Small Intestine, unspecified C18.0 Caecum Ileocaecal valve; Ileocaecal junction C18.1 Appendix C18.2 Ascending colon Right colon C18.4 Transverse colon C18.5 Splenic flexure C18.6 Descending colon Left colon C18.7 Sigmoid colon Sigmoid NOS; Sigmoid flexure of colon; Pelvic colon C18.8 Overlapping lesion of colon C18.9 Colon, unspecified Large intestine; Large Bowel MOS C19.X Malignant neoplasm of rectosigmoid junction C20.9 Rectum Rectal ampulla C20.X Malignant neoplasm of rectum C20.X C22.9 Malignant neoplasm, liver, unspecified C22.9 C23.X Malignant neoplasm of gall bladder C23.X C24.9 Malignant neoplasm, biliary tract, unspecified C24.9 C25.9 Malignant neoplasm, pancreas, unspecified C25.9 C26.9 Malignant neoplasm, ill-defined sites within C26.9 the digestive system C31.9 Malignant neoplasm, accessory sinus, unspecified C31.9 C32.9 Larynx unspecified C33.X Malignant neoplasm of trachea C33.X C34.9 Solitary malignant fibrous tumour of the lung 11

31 C37.X Malignant neoplasm of thymus C39.9 Malignant neoplasm, ill-defined sites within the respiratory system C40.0 Scapula and long bones of upper limbs Includes: Glenoid, Humerus, Ulna, Radius C40.1 Short bones of upper limb Includes: Carpal, Metacarpal, Phalanges C40.2 Long bones of lower limb Includes: Femur, Tibia, Fibula C40.3 Short bones of lower limb Includes: Metatarsus, Phalanges, Tarsus C40.9 Malignant neoplasm, bone and articular cartilage of limb, unspecified C40.9 C41.0 Bones of skull and face Includes: orbital bones C41.2 Vertebral column Includes: Cervical, Thoracic, Lumbar spine C41.3 Rib, sternum and clavicle C41.4 Pelvic bones, sacrum and coccyx Includes: Ilium, Ischium, Pubis, Acetabulum C41.9 Malignant neoplasm, bone and articular cartilage, unspecified C41.9 C44.0 Dermatofibrosarcoma C44.3 Skin of other and unspecified parts of face C44.4 Skin of scalp and neck C44.5 Skin of trunk C44.6 Skin of Upper limb, including shoulder C44.7 Skin of Lower limb, including hip C44.9 Malignant neoplasm, of skin, unspecified C44.9 C47.1 Peripheral Nerves of Upper limb, including shoulder C47.2 Peripheral Nerves of Lower limb including hip C47.5 Peripheral Nerves of pelvis C47.9 Malignant neoplasm, peripheral nerves and autonomic nervous system, unspec C47.9 C48.0 Retroperitoneal C48.2 Peritoneum, unspecified Includes: Intraperitoneal C49.0 Connective and soft tissue of head, face and neck Includes: Ear, eyelid C49.1 Connective and soft tissue of upper limb, Includes: Shoulder girdle, upper arm, elbow, including shoulder forearm, hand / wrist C49.2 Connective and soft tissue of lower limb, including hip Includes: Thigh, knee, lower leg, ankle / foot C49.3 Connective and soft tissue of thorax Includes: Axilla, diaphragm, great vessels, intrathoracic C49.4 Connective and soft tissue of abdomen Includes: Abdominal wall, hypochondrium C49.5 Connective and soft tissue of pelvis Includes: Buttock, groin, perineum C49.6 Connective and soft tissue of trunk, unspecified Includes: Upper trunk, lower trunk, back NOS C49.8 Overlapping lesion of connective and soft tissue C49.9 Connective and soft tissue, unspecified C50.0 Phylloides tumour C50.9 Malignant neoplasm, breast, unspecified C54.1 Endometrium C51.9 Malignant neoplasm, vulva, unspecified C53.9 Leiomyosarcoma of the cervix 12

32 C54.9 Malignant neoplasm, corpus uteri, unspecified C55.9 Uterus, part unspecified C54.9 C56.X Malignant neoplasm of ovary C56.X Malignant neoplasm, female genital organ, C57.9 C57.9 unspecified C58.X Malignant neoplasm of placenta C58.X C60.9 Malignant neoplasm, penis, unspecified C60.9 C61.X Prostate C62.9 Malignant neoplasm, testis, unspecified C62.9 C63.1 Liposarcoma of the spermatic cord C63.9 Malignant neoplasm, male genital organ, unspecified C64.X Malignant neoplasm of kidney, except renal pelvis C65.X Malignant neoplasm of renal pelvis C66.X C67.9 Malignant neoplasm of ureter Malignant neoplasm, bladder, unspecified C63.9 C68.9 Malignant neoplasm, urinary organ, unspecified C68.9 C69.6 Orbit Includes: Connective tissue of orbit C69.9 Malignant neoplasm, eye, unspecified C70.9 Malignant neoplasm, meninges, unspecified C71.9 Malignant neoplasm, brain, unspecified C72.9 Malignant neoplasm, central nervous system, unspecified C73.X Malignant neoplasm of thyroid gland C74.9 Malignant neoplasm, adrenal gland, unspecified C75.9 Malignant neoplasm, endocrine gland, unspecified C77.9 Malignant neoplasm, lymph node, unspecified C80.X Malignant neoplasm of unspecified site C96.9 Malignant neoplasm of lymphoid, haematopoietic C99.X Not recorded Related Data Items: 13

33 Location of Sarcoma Main Source of Data Item Standard: The National Cancer Audit Datasets developed by the Scottish Pathology Network supported by Information Services. Definition: This indicates the location of the sarcoma within a given site. Field Name: SITELOCATION Field Type: Characters Field Length: 3 Notes for Users: Required for QPI(s): 5 If location of Sarcoma is not clear; seek clarification from the relevant Clinician. Code Value Sub-Value Notes on Inclusion 01A Intraosseous Located inside of the bone Bone 01B Extraosseous Located outside of the bone 02A Cutaneous 02B Subcutaneous Soft Tissue 02C Superficial to Fascia 02D Deep to Fascia 03 GIST 96 Not applicable Primary location known 99 Not recorded Related Data Items: 14

34 Date of Histological Diagnosis {Sarcoma} Main Source of Data Item Standard: The National Audit Cancer Datasets developed by the regional Cancer Networks supported by Information Services. Definition: This is the date that the histological/cytological microscopic examination of the specimen to determine the presence of malignancy and the classification of the malignant tumour was performed. Field Name: DIAGDATE Format: Date (DD/MM/CCYY) Field length: 10 Notes for Users: Required for QPI(s): 1 11 Required for national survival analysis and national comparative analysis. There may be more than one biopsy/histology report. The first histology report should be recorded as the definitive report if prior to treatment. If no histological diagnosis was made, record as 10/10/1010 (Not applicable) If the exact date is not documented, record as 09/09/0909 (Not recorded). The date recorded is the date the procedure was performed, not the date the report was issued. Related Data Items: 15